Investor Centre

Clinical stage drug developer Syntara Limited (formerly Pharmaxis Ltd; ASX: PXS)¹ has received a R&D tax incentive of $5,205,123 in relation to the 2023 financial year. The Company’s cash balances will increase by approximately $700k after repayment of the $4.4 million loan and associated charges advanced by Paddington Street Finance in August 2023.

Pharmaxis CEO Gary Phillips said, “The R&D tax incentive is a significant source of non-dilutive funding for the Company’s clinical development pipeline including PXS-5505 in myelofibrosis where the next arm of a phase 2 trial in combination with standard of care is expected to shortly dose its first patients.” 

1. Syntara Limited was renamed from Pharmaxis Ltd on 4 December 2023. The new company name and code (SNT) will be effective on the ASX on 8 December 2023.

Clinical stage drug developer Syntara Limited today announced that the Australian Securities and Investment Commission has issued a Certificate of Registration on Change of Name from Pharmaxis Ltd to Syntara Limited.  This follows approval at last week’s 2023 annual general meeting where the resolution to change the name was supported by 98% of voting shareholders.

The change in the Company’s ASX code from PXS to SNT is currently being processed by the ASX, with trading under the new code expected to commence by Friday 8 December 2023.